MIROMATRIX MEDICAL INC (MIRO) Stock Price, Quote, News and Overview
NASDAQ:MIRO - Nasdaq - US60471P1084 - Common Stock - Currency: USD
MIRO Quote, Performance and Key Statistics
3.39
+0.02 (+0.59%)
The current stock price of MIRO is 3.39 USD. In the past month the price increased by 1.5%. In the past year, price increased by 17.71%.
MIRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
| DHR | DANAHER CORP | 28.07 | 151.18B | ||
| A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
| IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
| WAT | WATERS CORP | 31.58 | 22.26B | ||
| ICLR | ICON PLC | 14.39 | 16.63B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
| ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
| RVTY | REVVITY INC | 23.23 | 13.85B | ||
| AVTR | AVANTOR INC | 17.3 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 10.72B |
Related stock screener links
About MIRO
Company Profile
Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.
Company Info
MIROMATRIX MEDICAL INC
6455 Flying Cloud Drive, Suite 107
Eden Prairie MINNESOTA US
CEO: Jeff Ross
Employees: 76
Company Website: https://www.miromatrix.com/
Phone: 16122027026
MIROMATRIX MEDICAL INC / MIRO FAQ
What is the stock price of MIROMATRIX MEDICAL INC today?
The current stock price of MIRO is 3.39 USD. The price increased by 0.59% in the last trading session.
What is the ticker symbol for MIROMATRIX MEDICAL INC stock?
The exchange symbol of MIROMATRIX MEDICAL INC is MIRO and it is listed on the Nasdaq exchange.
On which exchange is MIRO stock listed?
MIRO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MIROMATRIX MEDICAL INC stock?
8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39. Check the MIROMATRIX MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MIROMATRIX MEDICAL INC worth?
MIROMATRIX MEDICAL INC (MIRO) has a market capitalization of 92.95M USD. This makes MIRO a Micro Cap stock.
How many employees does MIROMATRIX MEDICAL INC have?
MIROMATRIX MEDICAL INC (MIRO) currently has 76 employees.
What are the support and resistance levels for MIROMATRIX MEDICAL INC (MIRO) stock?
MIROMATRIX MEDICAL INC (MIRO) has a support level at 3.38 and a resistance level at 3.4. Check the full technical report for a detailed analysis of MIRO support and resistance levels.
Is MIROMATRIX MEDICAL INC (MIRO) expected to grow?
The Revenue of MIROMATRIX MEDICAL INC (MIRO) is expected to decline by -6.67% in the next year. Check the estimates tab for more information on the MIRO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MIROMATRIX MEDICAL INC (MIRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MIRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MIRO, evaluating the profitability, health, valuation and growth aspects
- MIROMATRIX MEDICAL INC (MIRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MIROMATRIX MEDICAL INC (MIRO) Sales and EPS estimates to see what analysts future expectations are.
- MIROMATRIX MEDICAL INC (MIRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MIROMATRIX MEDICAL INC (MIRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- MIROMATRIX MEDICAL INC (MIRO) Stock Chart to make your own analysis
- MIROMATRIX MEDICAL INC (MIRO) Latest news and press-releases to stay up to date.
Does MIROMATRIX MEDICAL INC (MIRO) stock pay dividends?
MIRO does not pay a dividend.
What is the Price/Earnings (PE) ratio of MIROMATRIX MEDICAL INC (MIRO)?
MIROMATRIX MEDICAL INC (MIRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
MIRO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MIRO. When comparing the yearly performance of all stocks, MIRO is one of the better performing stocks in the market, outperforming 96.98% of all stocks.
MIRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MIRO. The financial health of MIRO is average, but there are quite some concerns on its profitability.
MIRO Financial Highlights
Over the last trailing twelve months MIRO reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 17.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| Debt/Equity | 0.03 |
MIRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to MIRO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 32.47% and a revenue growth -6.67% for MIRO